Raymond James Financial
INDV icon

Raymond James Financial’s Indivior Pharmaceuticals INDV Stock Holding History

Raymond James Financial’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87M Buy
143,073
+120,595
+537% +$4.37M ﹤0.01% 2606
2026
Q1 		$685K Sell
22,478
-38,347
-63% -$1.27M ﹤0.01% 4127
2025
Q4 		$2.18M Buy
60,825
+12,053
+25% +$368K ﹤0.01% 3210
2025
Q3 		$1.18M Buy
48,772
+47,037
+2,711% +$984K ﹤0.01% 3579
2025
Q2 		$25.6K Buy
+1,735
New +$20.2K ﹤0.01% 5489

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's INDV Position: Q2 2026 in Review

Raymond James Financial increased its Indivior Pharmaceuticals (INDV) stake by 537% in Q2 2026, buying an estimated $4.37M and bringing the position to 143,073 shares worth $5.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2606.

Raymond James Financial first reported a position in INDV in Q2 2025 and has held it in 5 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Raymond James Financial held 143,073 shares of Indivior Pharmaceuticals worth $5.87M as of Q2 2026.
  • Raymond James Financial bought 120,595 Indivior Pharmaceuticals shares in Q2 2026, an estimated $4.37M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2606 holding.
  • Raymond James Financial first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.